SPRY2 and cancer: We suggest though the application results of precision cancer network analysis and literature that molecular interplays between “SYNE1 and IFITM1” may lead to capecitabine resistance of cancer cell lines, while weakening the molecular regulatory interactions between “SPRY2 and ETV1” and “SLPI and PTK1B” induce capecitabine-resistance in cell lines.